BlackRock Institutional Trust’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-600,132
| Closed | -$1.78M | – | 3940 |
|
|
2016
Q3 | $1.78M | Sell |
600,132
-10,539
| -2% | -$18.3K | ﹤0.01% | 3097 |
|
|
2016
Q2 | $910K | Sell |
610,671
-153,495
| -20% | -$351K | ﹤0.01% | 3340 |
|
|
2016
Q1 | $2.83M | Sell |
764,166
-1,361
| -0.2% | -$8.43K | ﹤0.01% | 2906 |
|
|
2015
Q4 | $7.73M | Buy |
765,527
+12,300
| +2% | +$148K | ﹤0.01% | 2491 |
|
|
2015
Q3 | $10.2M | Buy |
753,227
+12,686
| +2% | +$226K | ﹤0.01% | 2285 |
|
|
2015
Q2 | $14M | Sell |
740,541
-67,424
| -8% | -$1.46M | ﹤0.01% | 2172 |
|
|
2015
Q1 | $21.1M | Sell |
807,965
-30
| -0% | -$763 | ﹤0.01% | 1894 |
|
|
2014
Q4 | $16.9M | Sell |
807,995
-47,835
| -6% | -$1.21M | ﹤0.01% | 2012 |
|
|
2014
Q3 | $28.6M | Buy |
855,830
+53,752
| +7% | +$1.67M | ﹤0.01% | 1651 |
|
|
2014
Q2 | $25.7M | Buy |
802,078
+40,866
| +5% | +$1.52M | ﹤0.01% | 1780 |
|
|
2014
Q1 | $35.2M | Buy |
761,212
+30,852
| +4% | +$1.81M | 0.01% | 1558 |
|
|
2013
Q4 | $51.8M | Buy |
730,360
+72,114
| +11% | +$5.51M | 0.01% | 1225 |
|
|
2013
Q3 | $56.4M | Buy |
658,246
+66,468
| +11% | +$5.63M | 0.01% | 1127 |
|
|
2013
Q2 | $37.5M | Buy |
+591,778
| New | +$31.4M | 0.01% | 1345 |
|
BlackRock Institutional Trust's AEGR Position: Q4 2016 in Review
BlackRock Institutional Trust sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 600,132 shares — an estimated $1.78M sold.
BlackRock Institutional Trust first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $56.4M in Q3 2013. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- BlackRock Institutional Trust reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- BlackRock Institutional Trust sold 600,132 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $1.78M.
- BlackRock Institutional Trust first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- BlackRock Institutional Trust's Aegerion Pharmaceuticals position peaked at $56.4M in Q3 2013.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.